Pharma: Page 50
-
Q&A
Why 23andMe's first solo clinical trial is a big deal
It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come.
By Taren Grom • Feb. 7, 2022 -
Home is where the trial is
Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials.
By Kelly Bilodeau • Feb. 7, 2022 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Retrieved from MaxPixel.
Pharma's pain points with AI
Looking beyond the buzz and at the challenges associated with AI.
By Meagan Parrish • Feb. 7, 2022 -
Ferring Pharmaceuticals president discusses the need for more funding in women's health research
Read why women's healthcare funding is such a challenge.
By Robin Robinson • Feb. 4, 2022 -
Retrieved from Google image.
OpinionIndustry executives predict the next 'blue oceans' in pharma
Where life science leaders see breakthroughs happening in the industry.
By Taren Grom • Feb. 4, 2022 -
Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics
With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.
By Robin Robinson • Feb. 3, 2022 -
Podcast
Woman of the Week: Syneos Health's president of commercial solutions, Michelle Keefe
How Michelle Keefe, president, commercial solutions at Syneos Health, steered her team into a rapid pivot during the pandemic.
By Taren Grom • Feb. 2, 2022 -
Opinion
Talent acquisition stays top of mind for pharma execs
From creating flexible work environments to looking outside the industry for new talent, pharma execs are shifting strategies to keep their teams afloat.
By Taren Grom • Feb. 1, 2022 -
Retrieved from Rare Disease.org.
Q&AFor the CEO of Travere, running a rare disease company is personal
To kick off Rare Disease month, we interview the CEO of Travere Therapeutics
By Kim Ribbink • Feb. 1, 2022 -
Opinion
Biopharma's R&D leaders on how technology can accelerate drug development
How emerging digital tools are providing enhanced clinical insights and improved trial results.
By Taren Grom • Jan. 27, 2022 -
Q&A
Sanofi's chief scientist on why 'this is the moment' for AI in Big Pharma
How a $5.2 billion AI investment is enabling the French pharma to accelerate drug development.
By Meagan Parrish • Jan. 27, 2022 -
Q&A
With its wealth of patient data, Walgreens is looking to disrupt the clinical trial space
How the mega-pharmacy’s clinical trials officer is looking to capitalize on its deep well of patient data to create an interconnected healthcare system of the future.
By Taren Grom • Jan. 26, 2022 -
Podcast
Woman of the Week: Janssen's Dr. Sylvie Laquerre
Why following the science is crucial when bringing new compounds to market.
By Taren Grom • Jan. 26, 2022 -
How AI is helping pharma solve some of its COVID problems
With the pressure still on pharma to innovate quickly and go digital, the use-cases for AI are increasing in stride.
By Meagan Parrish • Jan. 25, 2022 -
Profile
One man's quest to boost the patient's role in clinical trials
How a personal diagnosis inspired Craig Lipset to transform patient involvement in medical research.
By Robin Robinson • Jan. 24, 2022 -
Retrieved from Google image.
OpinionLeaders predict improving patient engagement will lead to growth opportunities
Why patient engagement is key to successful business growth.
By Taren Grom • Jan. 24, 2022 -
Retrieved from Google image.
ProfileEvofem CEO Saundra Pelletier aims to level the playing field between men's and women's health
Evofem CEO and PharmaVoice100, Saundra Pelletier, discusses funding challenges for women's health.
By Alexandra Pecci • Jan. 23, 2022 -
What the opera can teach pharma about patient communication
With his opera knowledge, Inozyme’s Director of Investor Relations Stefan Riley uses his unique perspective to tell the company's compelling story.
By Kim Ribbink • Jan. 23, 2022 -
Podcast
Woman of the Week: Pfizer CMO Dr. Aida Habtezion
Pfizer's CMO shares her experiences transforming the company's R&D culture and improving health equity
By Taren Grom • Jan. 19, 2022 -
Profile
Vaxxinity looks to pioneer the next revolution in pharma
With a one-of-a-kind platform and novel candidates for major indications, Vaxxinity wants to disrupt the industry’s paradigm of success.
By Meagan Parrish • Jan. 14, 2022 -
Retrieved from Google image.
OpinionPharma execs reveal the industry's most pressing issues
Several market factors — including COVID — are driving changes and trends in the industry.
By Taren Grom • Jan. 14, 2022 -
Pharma M&A stagnated in 2021 — here's what could help it rebound
There are plenty of reasons pharma could get its M&A groove back in 2022.
By Meagan Parrish • Jan. 13, 2022 -
Welcome to the new PharmaVoice
A similar mission, a new format, and our plans for PharmaVoice's next chapter.
By Davide Savenije • Jan. 13, 2022 -
5 trends shaping clinical trial regulations in 2022
As agencies respond to innovations in pharma, notable shifts in 2022 are on the way.
By Meagan Parrish • Jan. 11, 2022 -
Biote CEO breaks down barriers in women's health
Women’s health is coming into sharper focus in 2022, but getting funding is still difficult.
By Robin Robinson • Jan. 11, 2022